| Phase I Single-blind Clinical Trial to Evaluate the Safety and Local Immune Activation of a Toll-like Receptor 5 Agonist (FLAMOD) Administered by Aerosol (NCT06681402) | Institut National de la Santé Et de la Recherche Médicale, France | 2025-04-14 |
| Purified Exosome Product (PEP) Injected Into the Hypodermis (NCT06429033) | Clinical Testing of Beverly Hills | 2025-04-14 |
| Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin (NCT07362030) | Guangdong Raynovent Biotech Co., Ltd | 2025-04-14 |
| ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia (NCT06364774) | Children's Hospital of Philadelphia | 2025-04-14 |
| A Study of Fosmanogepix in Healthy Adult Chinese Subjects (NCT06961708) | Basilea Pharmaceutica | 2025-04-14 |
| A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis (NCT06903065) | Hoffmann-La Roche | 2025-04-14 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants (NCT06797375) | Rallybio | 2025-04-14 |
| Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use (NCT06920238) | Trustees of Dartmouth College | 2025-04-13 |
| Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) (NCT06760481) | M.D. Anderson Cancer Center | 2025-04-13 |
| Palatability Study of Five Formulations of Benzydamine HCl Lozenges (NCT07199543) | Aziende Chimiche Riunite Angelini Francesco S.p.A | 2025-04-13 |
| A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour (NCT06888830) | Shanghai Junshi Bioscience Co., Ltd. | 2025-04-11 |
| A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia (NCT07556757) | ImmunityBio, Inc. | 2025-04-11 |
| Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function (NCT07141030) | Gan & Lee Pharmaceuticals. | 2025-04-11 |
| A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment (NCT06987500) | Evopoint Biosciences Inc. | 2025-04-11 |
| Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults (NCT06429930) | Pharmosa Biopharm Inc. | 2025-04-11 |
| Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion (NCT06968572) | Haisco Pharmaceutical Group Co., Ltd. | 2025-04-11 |
| Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (NCT06235567) | Maanasa Indaram, MD | 2025-04-11 |
| Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers (NCT06874205) | National Institute of Mental Health (NIMH) | 2025-04-11 |
| UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies (NCT06743503) | Nanjing IASO Biotechnology Co., Ltd. | 2025-04-11 |
| Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C (NCT06821503) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-04-11 |
| First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors (NCT06877650) | Shanghai JMT-Bio Inc. | 2025-04-11 |
| A Study to Assess the Safety of ARGX-213 in Healthy Volunteers (NCT06968338) | argenx | 2025-04-11 |
| Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial (NCT06901102) | Mansoura University | 2025-04-10 |
| A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations (NCT06800196) | KinoTeck Therapeutics Co., Ltd | 2025-04-10 |
| A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors (NCT06970795) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-04-10 |
| Effect of NAE on Polycystic Ovarian Syndrome (PCOS) (NCT07603505) | Jinnah Sindh Medical University | 2025-04-10 |
| A Clinical Study of Arfolitixorin in Patients With mCRC (NCT06922383) | Isofol Medical AB | 2025-04-10 |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases (NCT07022197) | Tianjin Medical University General Hospital | 2025-04-10 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA (NCT06603987) | Stella Pharma Corporation | 2025-04-10 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors (NCT06714617) | SystImmune Inc. | 2025-04-10 |
| SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (NCT06622005) | Roswell Park Cancer Institute | 2025-04-10 |
| Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma (NCT06956716) | Zhejiang University | 2025-04-09 |
| Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma (NCT06995105) | Zhejiang University | 2025-04-09 |
| A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE) (NCT06917742) | Capstan Therapeutics | 2025-04-09 |
| A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity (NCT06916065) | Eli Lilly and Company | 2025-04-09 |
| Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function (NCT06911320) | Atea Pharmaceuticals, Inc. | 2025-04-09 |
| Clinical Studies for the Treatment of Advanced Solid Tumors (NCT06825494) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2025-04-08 |
| A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects (NCT06883695) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2025-04-08 |
| Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants (NCT06910709) | Amgen | 2025-04-08 |
| A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma (NCT06501911) | University of Nebraska | 2025-04-08 |
| Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure (NCT07087223) | Peking University Cancer Hospital & Institute | 2025-04-08 |
| A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer (NCT06840535) | Philogen S.p.A. | 2025-04-08 |
| A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies (NCT06708897) | Lomond Therapeutics Holdings, Inc. | 2025-04-08 |
| Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) (NCT06300502) | Massachusetts General Hospital | 2025-04-08 |
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007 (NCT06899230) | iQure Australia Pty Ltd | 2025-04-08 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin (NCT06921941) | Atea Pharmaceuticals, Inc. | 2025-04-08 |
| A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects (NCT06884072) | Abbisko Therapeutics Co, Ltd | 2025-04-08 |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer (NCT06287775) | National Cancer Institute (NCI) | 2025-04-08 |
| Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid (NCT06916143) | Eli Lilly and Company | 2025-04-08 |
| Exploratory Clinical Study of Claudin18.2-Targeted CAR-DC and CAR-T Therapy in Advanced Colorectal Cancer (NCT06946615) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-04-08 |
| CAR-NK Cells (CL-NK-001) in Pancreatic Cancer (NCT06816823) | Changhai Hospital | 2025-04-07 |
| A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010) (NCT06814132) | Merck Sharp & Dohme LLC | 2025-04-07 |
| DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma (NCT06892678) | Montefiore Medical Center | 2025-04-07 |
| NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (NCT06459869) | Akamis Bio | 2025-04-07 |
| A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men and Women (NCT06916702) | Boehringer Ingelheim | 2025-04-07 |
| A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors (NCT06877533) | iTeos Belgium SA | 2025-04-07 |
| CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) (NCT06834282) | CERo Therapeutics Holdings, Inc. | 2025-04-07 |
| Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis (NCT06871904) | Ziauddin University | 2025-04-07 |
| Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase (NCT07091747) | Federal University of Latin American Integration | 2025-04-07 |
| A Study of SRSD216 in Patients With Elevated Lipoprotein (a) (NCT07172646) | Sirius Therapeutics Co., Ltd. | 2025-04-07 |
| A Phase I Study to Evaluate LIFE-001 (NCT06904807) | LifeMine Therapeutics | 2025-04-07 |
| Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 (NCT06714006) | PYC Therapeutics | 2025-04-07 |
| BC008-1A Injection for Recurrent CNS WHO G4 Glioma (NCT06773481) | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | 2025-04-07 |
| A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010) (NCT06814119) | Merck Sharp & Dohme LLC | 2025-04-07 |
| AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis (NCT06665165) | Amylyx Pharmaceuticals Inc. | 2025-04-07 |
| Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants (NCT06895993) | Sichuan Huiyu Pharmaceutical Co., Ltd | 2025-04-07 |
| Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial (NCT06834126) | City of Hope Medical Center | 2025-04-07 |
| Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma (NCT06934889) | Memorial Sloan Kettering Cancer Center | 2025-04-07 |
| A Mass Balance Study of [14C]ABSK011 (NCT06896760) | Abbisko Therapeutics Co, Ltd | 2025-04-07 |
| A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration (NCT06825858) | Chengdu Origen Biotechnology Co., Ltd. | 2025-04-07 |
| An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab (NCT06908577) | AstraZeneca | 2025-04-07 |
| Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers (NCT06864793) | Qilu Pharmaceutical Co., Ltd. | 2025-04-06 |
| Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing (NCT06924385) | Xiamen Amoytop Biotech Co., Ltd. | 2025-04-06 |
| Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults (NCT07416955) | Kashiv BioSciences, LLC | 2025-04-05 |
| Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant (NCT06523699) | Washington University School of Medicine | 2025-04-04 |
| Combining Dexmedetomidine Infusion and Paragastric Autonomic Neural Block to Enhance Postoperative Recovery in Patients Undergoing Laparoscopic Sleeve Gastrectomy (NCT06970678) | Alexandria University | 2025-04-04 |
| A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer (NCT06732856) | Asan Medical Center | 2025-04-04 |
| A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals (NCT06932523) | Shanghai Institute Of Biological Products | 2025-04-04 |
| Cannabidiol in Sickle Cell Disease (NCT06930703) | Icahn School of Medicine at Mount Sinai | 2025-04-03 |
| A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma (NCT07713290) | Beijing Gene Key Life Technology Co., Ltd | 2025-04-03 |
| Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars (NCT06751433) | Herbarium Laboratorio Botanico Ltda | 2025-04-03 |
| A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (NCT06889701) | TenNor Therapeutics Inc. | 2025-04-03 |
| A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults (NCT06911788) | Pfizer | 2025-04-03 |
| Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia (NCT05158114) | The Foundation for Orthopaedics and Regenerative Medicine | 2025-04-03 |
| Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants (NCT06906809) | BeiGene | 2025-04-03 |
| Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC (NCT06348797) | Sichuan University | 2025-04-03 |
| A Phase 1 Study of S-4321 (NCT06877611) | Seismic Therapeutic AU Pty Ltd | 2025-04-03 |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors (NCT06726148) | Novartis Pharmaceuticals | 2025-04-03 |
| Evaluation of SYS6005 in Patients With Advanced Malignant Tumor (NCT06958679) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-04-03 |
| Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Ovarian Failure (NCT05158933) | The Foundation for Orthopaedics and Regenerative Medicine | 2025-04-03 |
| A First-in-Human Phase I Trial of OX118 in Healthy Volunteers (NCT07020156) | Oxion Biologics AB | 2025-04-03 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants (NCT06895343) | AbbVie | 2025-04-03 |
| Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects (NCT06884514) | University Hospital, Basel, Switzerland | 2025-04-03 |
| Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension (NCT06823947) | Kyowa Kirin Co., Ltd. | 2025-04-03 |
| Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial (NCT06863194) | Mansoura University | 2025-04-03 |
| Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC (NCT06868732) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2025-04-02 |
| AZD5305 hADME in Patients With Advanced Solid Malignancies (NCT06713369) | AstraZeneca | 2025-04-02 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011 (NCT06925919) | IDBiologics, Inc. | 2025-04-02 |
| A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors (NCT06907628) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-04-02 |
| A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours. (NCT06815575) | Racura Oncology Ltd | 2025-04-02 |